N-乙酰-L-亮氨酸治疗C型尼曼-匹克病:一项跨国双盲随机安慰剂对照交叉研究
本文描述了一项跨国双盲随机安慰剂对照交叉III期试验(IB1001-301)的研究方案,纳入4岁及以上经基因确诊的C型尼曼-匹克病(NPC)患者,在16个试验中心开展。患者按1:1随机分配至IB1001后安慰剂或安慰剂后IB1001两种治疗序列,每序列治疗12周。主要疗效终点基于共济失调评估与评级量表,次要结局包括小脑功能评定量表、临床总体印象和生活质量评估。
要点
- IB1001-301为跨国双盲随机安慰剂对照交叉III期试验,纳入4岁及以上基因确诊的NPC患者。
- 患者按1:1随机分配至IB1001后安慰剂或相反序列,每序列治疗12周,共16个试验中心。
- 主要疗效终点为共济失调评估与评级量表,次要结局包括小脑功能量表、临床总体印象和生活质量。
核心结论
- 本安慰剂对照交叉试验将评估IB1001治疗NPC的风险/获益特征,并为其作为其他罕见和常见神经系统疾病治疗范式的适用性提供信息。
研究设计与样本
- 跨国双盲随机安慰剂对照交叉III期试验(IB1001-301),在16个试验中心纳入4岁及以上经基因确诊的NPC患者。
- 患者在基线期评估后按1:1随机分配至两种治疗序列之一:IB1001后安慰剂,或安慰剂后IB1001,每序列包含12周治疗期。
主要发现
- 临床前研究、观察性研究和IIb期临床试验已表明IB1001可快速改善儿童和成人NPC患者的症状、功能和生活质量,且安全且耐受良好。
关键数值与推荐
- 主要疗效终点基于共济失调评估与评级量表(Scale for the Assessment and Rating of Ataxia)。
- 次要结局包括小脑功能评定量表、临床总体印象和生活质量评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative lysosomal disease characterized by multiple symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in various studies, including animal models of NPC, observational clinical case studies, and a multinational, rater-blinded phase IIb clinical trial. Here, we describe the development of a study protocol (Sponsor Code "IB1001-301") for the chronic treatment of symptoms in adult and pediatric patients with NPC. METHODS: This multinational double-blind randomized placebo-controlled crossover phase III study will enroll patients with a genetically confirmed diagnosis of NPC patients aged 4 years and older across 16 trial sites. Patients are assessed during a baseline period and then randomized (1:1) to one of two treatment sequences: IB1001 followed by placebo or vice versa. Each sequence consists of a 12-week treatment period. The primary efficacy endpoint is based on the Scale for the Assessment and Rating of Ataxia, and secondary outcomes include cerebellar functional rating scales, clinical global impression, and quality of life assessments. DISCUSSION: Pre-clinical as well as observational and phase IIb clinical trials have previously demonstrated that IB1001 rapidly improved symptoms, functioning, and quality of life for pediatric and adult NPC patients and is safe and well tolerated. In this placebo-controlled cross-over trial, the risk/benefit profile of IB1001 for NPC will be evaluated. It will also give information about the applicability of IB1001 as a therapeutic paradigm for other rare and common neurological disorders. TRIAL REGISTRATIONS: The trial (IB1001-301) has been registered at www. CLINICALTRIALS: gov (NCT05163288) and www.clinicaltrialsregister.eu (EudraCT: 2021-005356-10). Registered on 20 December 2021.
引用
- Fields T, M Bremova T, Billington I, et al. N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study. Trials. 2023. PMID: 37248494. doi:10.1186/s13063-023-07399-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。